Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    NCT02353143
Previous Study | Return to List | Next Study

Study of MEN1112 Intravenous Infusion in Relapsed or Refractory Acute Myeloid Leukemia (ARMY)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02353143
Recruitment Status : Terminated (The Sponsor accepted the iDSMB recommendation to terminate the study due to evidence of unpredictable liver toxicity and meaningful target engagement not translating into any clinical objective response.)
First Posted : February 2, 2015
Last Update Posted : July 9, 2021
Sponsor:
Information provided by (Responsible Party):
Menarini Group

Tracking Information
First Submitted Date  ICMJE January 14, 2015
First Posted Date  ICMJE February 2, 2015
Last Update Posted Date July 9, 2021
Actual Study Start Date  ICMJE December 2014
Actual Primary Completion Date April 9, 2021   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: January 28, 2021)
  • Dose limiting toxicity (DLT) [ Time Frame: over 3 weeks after the first dose ]
    Identification of DLT defined as an adverse event occurring during the first treatment cycle, judged to be related to MEN1112 and meeting any of the following criteria:
    • Grade 3 non-haematological toxicity lasting more than 7 days
    • Grade ≥ 4 non-haematological toxicity.
  • Maximum tolerated dose (MTD) [ Time Frame: over 3 weeks after the first dose ]
    Identification of MTD defined as one dose level below the Maximum Administered Dose (i.e. one dose level below the one at which ≥ 2 DLTs out of 6 treated patients occur).
Original Primary Outcome Measures  ICMJE
 (submitted: January 28, 2015)
  • Dose limiting toxicity (DLT) [ Time Frame: over 3 weeks after the first dose ]
    DLT is defined as an adverse event occurring within the first induction cycle, judged to be related to MEN1112 and meeting any of the following criteria:
    • Grade 3 non- haematological toxicity lasting more than 7 days.
    • Grade 4 non- haematological toxicity
  • Maximum tolerated dose (MTD) [ Time Frame: over 3 weeks after the first dose ]
    MTD is defined as one dose level below the Maximum Administered Dose (i.e. one dose level below the one at which ≥ 2 DLTs out of 6 treated patients occur).
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: January 28, 2021)
  • Treatment Emergent Signs and Symptoms (TESSs) [ Time Frame: 6 months ]
    Incidence, severity, seriousness and treatment related causality of Treatment Emergent Signs and Symptoms (TESSs)
  • MEN1112 Pharmacokinetic (PK) parameter Cmax [ Time Frame: Under ramp-up schedule during Cycle 1, at the end of Day 1 and 2 infusions (when applicable) and at the end of Day 3 infusion; and under one-shot schedule during Cycle 2, at the end of the third infusion (Day 36). Each cycle lasts 21 days. ]
    Cmax is the maximum serum drug concentration.
  • MEN1112 PK parameter AUC (0-t) [ Time Frame: Under ramp-up schedule during Cycle 1, at the end of Day 1 and 2 infusions (when applicable) and at the end of Day 3 infusion; and under one-shot schedule during Cycle 2, at the end of the third infusion (Day 36). Each cycle lasts 21 days. ]
    AUC (0-t) is the area under the serum concentration-time curve from time 0 extrapolated to t time
  • MEN1112 PK parameter AUC (0-∞) [ Time Frame: Under ramp-up schedule during Cycle 1, at the end of Day 1 and 2 infusions (when applicable) and at the end of Day 3 infusion; and under one-shot schedule during Cycle 2, at the end of the third infusion (Day 36). Each cycle lasts 21 days. ]
    AUC (0-∞) is the area under the serum concentration-time curve from time 0 extrapolated to infinite time
  • MEN1112 PK parameter t1/2 [ Time Frame: Under ramp-up schedule during Cycle 1, at the end of Day 1 and 2 infusions (when applicable) and at the end of Day 3 infusion; and under one-shot schedule during Cycle 2, at the end of the third infusion (Day 36). Each cycle lasts 21 days. ]
    t1/2 is the drug elimination half-life
  • Complete remission (CR) rate [ Time Frame: 6 months ]
    CR rate at any time point, where CR is defined as: bone marrow blasts <5%, absence of extramedullary disease, absolute neutrophil count >1 x 109/L and platelet count > 100 x 109/L
  • Best response rate [ Time Frame: 6 months ]
    best observed response at any time point between CR, CRi [where CRi is defined as: all criteria for CR except residual thrombocytopenia (platelets <100 x 109/L) and/or neutropenia (absolute neutrophil count <1 x 109/L)] and partial remission [(PR): all haematological criteria for CR with bone marrow blasts 5-25% and decrease of pre-treatment bone marrow blast percentage by at least 50%].
  • Overall survival [ Time Frame: 6 months ]
    number of days between the first study drug administration and death from any cause
Original Secondary Outcome Measures  ICMJE
 (submitted: January 28, 2015)
  • Treatment Emergent Signs and Symptoms (TESSs) [ Time Frame: 6 months ]
    Incidence, severity, seriousness and treatment-causality of Treatment Emergent Signs and Symptoms (TESSs)
  • MEN1112 Pharmacokinetic (PK) parameter AUC0-∞ [ Time Frame: Estimated maximum time frame: 4 weeks ]
    AUC0-∞ is the area under the serum concentration-time curve from time zero extrapolated to infinite time.
  • MEN1112 PK parameter Cmax [ Time Frame: Estimated maximum time frame: 4 weeks ]
    Cmax is the maximum serum drug concentration
  • MEN1112 PK parameter t1/2 [ Time Frame: Estimated maximum time frame: 4 weeks ]
    t1/2 is the drug elimination half-life
  • Complete remission (CR) rate [ Time Frame: 6 months ]
    CR rate at any time point, where CR is defined as: bone marrow blasts <5%, absence of extramedullary disease, absolute neutrophil count >1 x 109/L and platelet count > 100 x 109/L
  • Best response rate [ Time Frame: 6 months ]
    best observed response at any time point between CR, CRi [where CRi is defined as: all criteria for CR except residual thrombocytopenia (platelets <100 x 109/L) and/or neutropenia (absolute neutrophil count <1 x 109/L)] and partial remission [(PR): all haematological criteria for CR with bone marrow blasts 5-25% and decrease of pre-treatment bone marrow blast percentage by at least 50%].
  • Overall survival [ Time Frame: 6 months ]
    number of days between the first study drug administration and death from any cause
Current Other Pre-specified Outcome Measures
 (submitted: January 28, 2015)
Immunogenicity of MEN1112 [ Time Frame: 64 days ]
Incidence of anti-MEN1112 auto-antibodies
Original Other Pre-specified Outcome Measures Same as current
 
Descriptive Information
Brief Title  ICMJE Study of MEN1112 Intravenous Infusion in Relapsed or Refractory Acute Myeloid Leukemia
Official Title  ICMJE First in Man Study With MEN1112, a CD157 Targeted Monoclonal Antibody, in Relapsed or Refractory Acute Myeloid Leukemia.
Brief Summary The purpose of this study is to assess the safety of MEN1112, given as intravenous infusion, in patients with relapsed or refractory AML. Pharmacokinetics, clinical activity and potential immunogenicity of MEN1112 will be evaluated as well.
Detailed Description

This trial is designed as an open label, non randomised, dose escalation and cohort expansion, first administration to human study to be conducted in approximately 20 European sites. The study is aiming to identify the Dose Limiting Toxicity (DLT) and Maximum Tolerated Dose (MTD), to assess the pharmacokinetics and to determine the clinical activity and potential immunogenicity of MEN1112, administered as IV infusion for two 21-day cycles.

Approximately 100 male and female ≥ 18 years-old patients, with a documented diagnosis of relapsed or refractory AML (not M3 FAB subtype), will be treated in the study, which consists of two steps.

Step 1 is the dose escalation phase according to a 3+3 patients cohort design. Incremental mg/Kg doses will be tested. Briefly, MEN1112 doses are to be administered to 3 patients; if no DLT is observed in a cohort of 3 DLT evaluable patients at a given dose level, the next cohort of 3 new patients will be treated with the next higher dose. In case of DLT occurrence by one of the three patients at any dose, the cohort will be expanded to 6 DLT evaluable patients at the same dose level. If two or more patients at a given dose level exhibit DLT, the dose escalation phase will be concluded as the MTD will be identified as one dose level below the one at which ≥ 2 DLT out of 6 treated patients occur.

Step 2 is the cohort expansion phase which will include patients treated at the MTD or the maximum dose level judged to be tolerable.

In each study Step, patients will be given two induction cycles of MEN1112 followed by a four-week End of Treatment period and a Follow-up period. In Step 1 and Step 2, DLT and MTD will be assessed when MEN1112 is given as a 'one shot' infusion (first group of patients) for all doses as well as a 'ramp up' administration to be infused in 3 days for the first two doses in Cycle 1 (second group of patients).

Along the study period, adverse events, changes in hematology/serum biochemistry parameters and bone marrow treatment response will represent the major clinical findings to be monitored on regular basis. The individual experimental clinical phase will last up to 6 months (except for female patients of childbearing potential that will undergo monthly pregnancy test until 6 months from the last study drug administration) encompassing approx. 40 planned visits at site, including Screening,Treatment, End of Treatment, Follow-up period and the End of Study visit.

Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 1
Study Design  ICMJE Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE
  • Recurrent Adult Acute Myeloid Leukemia
  • Acute Myeloid Leukemia, in Relapse
Intervention  ICMJE Drug: MEN1112

Intravenous infusion of MEN1112 pro/Kg body weight dose will be administered for two 21-day cycles; MEN1112 dose is administered as' one shot infusion' (first group of patients) and as a dose to be infused in 3 days for the first two doses in Cycle 1 (second group of patients).

Two treatment cycles will be followed by a 4-week End of Treatment Period and a Follow-up period. The individual treatment/observation period is six months (except for female patients of childbearing potential that will undergo monthly pregnancy test until 6 months from the last study drug administration).

Study Arms  ICMJE Experimental: MEN1112
Dose escalation will occur using a standard 3+3 dose escalation approach, beginning in dose level I with dose cohorts and rules for escalation
Intervention: Drug: MEN1112
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Terminated
Actual Enrollment  ICMJE
 (submitted: May 11, 2021)
71
Original Estimated Enrollment  ICMJE
 (submitted: January 28, 2015)
50
Actual Study Completion Date  ICMJE April 9, 2021
Actual Primary Completion Date April 9, 2021   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Male or female patients aged ≥ 18 years.
  • Documented definitive diagnosis of AML (according to WHO criteria, 2008) that is relapsed/refractory to standard treatment, for which no standard therapy is available or the patient refuses standard therapy.
  • WBC count ≤ 10 x 109/L at Visit 1/Day 1; hydroxyurea is allowed to lower WBC count.
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2 at Visit1/Day 1.
  • Life expectancy of at least 2 months.
  • Adequate renal and hepatic laboratory assessments: Aspartate aminotransferase (AST), alanine aminotransferase (ALT) and alkaline phosphatase (ALP) ≤3.0 × ULN, unless considered due to leukemic organ involvement, Total Bilirubin ≤2.0 × ULN, Serum creatinine ≤2.0 × ULN.
  • Able to give written informed consent before any study related procedure

Exclusion Criteria:

  • Acute promyelocytic leukaemia (French-American-British M3 classification).
  • Active central nervous system involvement.
  • Haematopoietic stem cell transplantation (HSCT) performed within 3 months prior to Screening Visit.
  • Active infection requiring intravenous antibiotics.
  • Life-threatening illnesses other than AML, uncontrolled medical conditions or organ system dysfunction which, in the investigator's opinion, could compromise the patient's safety or interfere with the patient's ability to comply with the study activities.
  • Anti-tumour therapy within 14 days of study Visit 1/Day 1, excluding hydroxyurea.
  • Prior participation in an investigational study (procedure or device) within 21 days of study Visit 1/Day 1.
  • Radiotherapy within 28 days prior to study Visit 1/Day 1 or scheduled along the study conduct.
  • Known history of human immunodeficiency virus (HIV) or active infection with hepatitis C virus (HCV) or hepatitis B virus (HBV).
  • Other active malignancies. History of malignancy in the last 12 months (except basal cell or squamous cell skin cancer or carcinoma in situ of the cervix or breast or non-melanoma skin cancer).
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Belgium,   France,   Germany,   Italy,   Spain
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT02353143
Other Study ID Numbers  ICMJE ARMY-1
2014-002433-59 ( EudraCT Number )
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Current Responsible Party Menarini Group
Original Responsible Party Same as current
Current Study Sponsor  ICMJE Menarini Group
Original Study Sponsor  ICMJE Same as current
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Chair: Adriano Venditti, Professor, MD Hematology Department, "Tor Vergata" University Viale Oxford, 81 00133 Rome, Italy
PRS Account Menarini Group
Verification Date July 2021

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP